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Abstract
T Cell Leukemia/Lymphoma 1A is expressed during B-cell differentiation and, when over-
expressed, acts as an oncogene in mouse (Tcl1a) and human (TCL1A) B-cell chronic lym-
phocytic leukemia (B-CLL) and T-cell prolymphocytic leukemia (T-PLL). Furthermore, in the
murine system Tcl1a is expressed in the ovary, testis and in pre-implantation embryos,
where it plays an important role in blastomere proliferation and in embryonic stem cell (ESC)
proliferation and self-renewal. We have also observed that Tcl1-/- adult mice exhibit alopecia
and deep ulcerations. This finding has led us to investigate the role of TCL1 in mouse skin
and hair follicles. We have found that TCL1 is expressed in the proliferative structure (i.e. the
secondary hair germ) and in the stem cell niche (i.e. the bulge) of the hair follicle during re-
generation phase and it is constitutively expressed in the basal layer of epidermis where it is
required for the correct proliferative–differentiation program of the keratinocytes (KCs). Tak-
ing advantage of the murine models we have generated, including the Tcl1-/- and the K14-
TCL1 transgenic mouse, we have analysed the function of TCL1 in mouse KCs and the
molecular pathways involved. We provide evidence that in the epidermal compartment TCL1
has a role in the regulation of KC proliferation, differentiation, and apoptosis. In particular, the
colony-forming efficiency (CFE) and the insulin-like growth factor 1 (IGF1)-induced prolifera-
tion are dramatically impaired, while apoptosis is increased, in KCs from Tcl1-/- mice when
compared to WT. Moreover, the expression of differentiation markers such as cytokeratin 6
(KRT6), filaggrin (FLG) and involucrin (IVL) are profoundly altered in mutant mice (Tcl1-/-).
Importantly, by over-expressing TCL1A in basal KCs of the K14-TCL1 transgenic mouse
model, we observed a significant rescue of cell proliferation, differentiation and apoptosis of
the mutant phenotype. Finally, we found TCL1 to act, at least in part, via increasing phospho-
ERK1/2 and decreasing phospho-P38 MAPK. Hence, our data demonstrate that regulated
levels of Tcl1a are necessary for the correct proliferation and differentiation of the interfollicu-
lar KCs.
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Introduction
Skin homeostasis is a complex process in which epidermal stem cells (SCs) self-renew and gen-
erate daughter cells, which proliferate, undergo terminal differentiation and eventually die.
Among the genes regulating epidermal homeostasis, we have previously described the role of
the Tcl1a gene in a mouse model [1]. TCL1A has been initially isolated as an oncogene involved
in human T-PLL and it is widely studied in B-CLL [2–8], albeit Tcl1-/- mice show a mild
impairment of B- and T-cell differentiation [9]. TCL1A overexpression in cancer or in mouse
models is tightly associated to proliferative/pro-survival conditions [10–12]. Further, TCL1
affects the proliferation/differentiation balance, the self-renewal ability and pluripotency of
murine embryonic stem cells (ESC) [13–18] and it is highly expressed in pre-implantation
embryo, allowing the progression beyond the 4-cell stage [19, 20].
In our previous study, we have shown that TCL1 affects both hair growth and epidermis
integrity [1]. We found that Tcl1a loss led to the proliferation impairment of transient amplify-
ing (TA) cells, in the regenerative phase of hair follicle, and to the lack of expression of the SC
marker CD34 in the bulge (i.e., the SC niche), thus affecting the ability to incorporate BrdU in
the slow-cycling SC and in TA cells. Additionally, Tcl1a was found to be expressed in the basal
layer of mouse epidermis, where its loss induced a differentiation/proliferation imbalance,
resulting in the aberrant co-expression of proliferation and apoptotic markers in the same cell.
As a consequence, adult Tcl1-/- mice developed skin defects, represented by early alopecia and
late ulcerations. Interestingly, the mutant phenotype was almost completely rescued by epider-
mal K14 promoter-driven TCL1A over-expression, in vivo [1].
TCL1 is known to enhance AKT Ser-473 phosphorylation and its nuclear translocation,
both in humans and in mice [21–24]. Furthermore, TCL1 acts as an NFkB activator, through
the interaction with p300, and as an inhibitor of AP1-dependent transcription, through the
direct interaction with cFOS and cJUN [25].
In this study we used the gene expression profile (GEP) analysis to unravel the pathways
that are affected by Tcl1a loss-of-function in epidermal keratinocytes (KCs) by comparing the
Tcl1-/- and the WTmouse models. Furthermore, we evaluated the reactivation of TCL1 in the
basal layer of epidermis in the K14-TCL1mouse model for its ability to rescue the aberrant
phenotype, both at the molecular and functional levels. We especially focused on proliferation/
differentiation/apoptosis functions and our findings show that TCL1 affects several growth
factor-induced pathways with the RAS-MAPK pathway resulting strongly involved. In particu-
lar, we found that TCL1 is essential for IGF1-induced proliferation of primary KCs and for
their clonogenic ability. Additionally, cleavage of apoptosis-related proteins such as Caspase 3
(CASP3) and Poly(ADP-ribose) polymerase 1 (PARP1) is increased in Tcl1-/- KCs. Alterations
in the expression pattern of differentiation markers, such as KRT6, FLG and IVL, are also
described. Interestingly, restoring the TCL1A expression in the K14-TCL1mouse model
almost completely reverts the aberrant phenotype.
Materials and methods
Animals
Wild Type C57bl/6 (WT), Tcl1-/- and K14-TCL1;Tcl1-/- (K14-TCL1)mice were studied [1]. All
experimental procedures, animal care and housing were conformed to European(Directive 86/
609/ECC and 2010/63/UE) and Italian (D.L. 116/92 and D.L. 26/2014) laws on theuse of ani-
mals in scientific research Animal experiments were approved by the IDI-IRCCS Animal Care
and Use Committee ‘Organismo Preposto al Benessere Animale’ (OPBA) and the protocol was
approved by the Italian Ministry of Health. All efforts were made to minimize suffering.
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RNA isolation
For gene expression experiments, skin patches of 1 cm2 were harvested three days’ post-depila-
tion (3dpd). The skin biopsy was excised and placed in PBS containing 1U/mL of dispase (BD
Biosciences, Belgium) and incubated overnight at 4˚C in gentle fluctuation. The epidermal
sheet was then separated from the dermis using sterile forceps and placed in 1mL of TRIZOL
Reagent (Life Technologies, UK). Total RNA was extracted following manufacturer’s protocol.
RNA quality was checked through agarose gel and quantification was obtained using Nano-
Drop spectrophotometer (Thermo Fisher Scientific, MA USA).
Microarray expression profile
Biotinylated cRNAs probes were prepared and hybridized to pan-genomic Affymetrix Mouse
Genome 430 2.0 arrays, as per manufacturer protocol (Affymetrix, Santa Clara, CA USA).
Three animals and three independent chips were used for each genotype. Unsupervised hierar-
chical analyses were performed using the BRB-Array Tools software (Biometric Research
Branch, National Cancer Institute) [26] and Partek Genomic Suitesoftware (Partek Inc.
St. Louis, MO, USA) for principal component analysis (PCA). To identify genes that were dif-
ferentially expressed betweenWT, Tcl1-/- and K14–TCL1 groups supervised analysis was per-
formed using ‘class comparison tools’ of BRB array tools. The random variance model was
applied to the filtered data sets. Genes with p-values less than 0.001 were considered statisti-
cally significant. Moreover, genes were excluded if their expression was less than 1.4 fold from
gene’s median value in at least 20% of the samples. The false discovery rate (FDR) was also esti-
mated for each gene using the method of Benjamini and Hochberg, to control for false posi-
tives [27]. Gene ontology (GO) and pathway analysis used two-sample t tests and random
variance model. Significant gene sets were found using LS/KS permutation test and Efron-Tib-
shirani’s GSA maxmean test. For gene categories identified by GO the threshold was P<0.005.
For pathway analysis, the threshold of determining significant gene sets was P<0.05. Gene sets
are defined by the Biocarta Pathway (https://cgap.nci.nih.gov/Pathways/BioCarta). Pathways
and GO analysis have been performed using the “Gene Set Expression Comparison” tool of
BRB array tools. According to the PLOS Data Availability policy, microarray data are depos-
ited at GEO (accession number GSE118345).
Real time PCR
Real Time quantification of target mRNAs relative to RNA polymerase II (RPII) mRNA was
performed with a SYBR Green 2X SensiMix One-Step Kits (Quantace, UK), using the ABI
PRISM 7000 detection system (Applied Biosystems, UK). cDNAs were made using 1μg total
RNA, 0.5μg oligo dT, 1μl ImProm-II Reverse Transcriptase (Promega, WI USA). 3μl of cDNA
diluted 1:7 were added in a 25μl total reaction mix. Primers for target genes (Krt6; cFos; Gjb2;
Dio2;Dusp1; Epgn; Rptn; S100a9; Sprr1b; Stk25) and reference gene (RPII) (MWG, Biotech,
Germany) were optimized for a final concentration of 50nM and are listed in S1 Table. The
following experimental run protocol was used: initial denaturation 95˚C for 10 min followed
by 40 cycles of denaturation 95˚C for 15sec and annealing 60˚C for 1min. RT-PCR products,
analyzed by gel electrophoresis, resulted in a single product of the expected length. In addition,
a melting curve analysis was performed, which confirmed the specificity of the reaction and
the absence of primer dimers. Relative gene expression was quantified as described in User
Bulletin #2 for the ABI PRISM 7000.
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Cell culture
Mouse KCs were isolated from the skin of newborn mice, as described [28], except that the epi-
dermis was dissociated following 0.05% DNase addition (Sigma-Aldrich, Italy). 5⇤10^5 KCs
were plated in T25 cell culture flask coated with mouse type IV collagen (BD Biosciences, Bel-
gium) and grown in Cnt-57 progenitor cell-targeted medium (CELLnTEC, Switzerland). At
subconfluence, cells were detached using TrypLE enzyme (Thermo Fisher Scientific, MA
USA) and either used for the experiments, or seeded for further passages at 2⇤10^5 cells in 5
mL medium.
Kinase assay
AKT kinase assay was performed following the manufacturer’s instruction (CycLex CY-1168,
MBL, Japan). Briefly, equal amounts of keratinocyte extract were added to the plate wells
together with ATP-containing kinase reaction buffer. After 60 minutes of incubation, wells
were washed and then were incubated with HRP-conjugated antibody for additional 60 min-
utes. After washing, wells were incubated with substrate reagent for 10 minutes. Finally, stop
solution was added and absorbance was measured using a plate reader at dual wavelengths of
450/540 nm (BIO-RADmodel 680).
Western blot analysis (WB)
1-cm2 epidermal samples were obtained as described for RNA isolation, lysed in RIPA buffer
and boiled in SDS sample buffer. 30-μg protein were separated in SDS-PAGE gels and trans-
ferred to nitrocellulose membranes (BIO-RAD). Membranes were incubated overnight at 4˚C
with primary antibodies followed by 1-hour incubation at room temperature with appropriate
HRP-conjugated secondary antibodies (Santa Cruz Biotechnology). Immuno-detection was
enhanced by chemiluminescence detection reagents (Thermo Scientific Pierce). Films were
scanned on a GS710 Calibrated Imaging Densitometer and absorbance of the bands was mea-
sured by means of Quantity One software version 4.1.1 (BIO-RAD). Antibody used are listed
in the S2 Table.
Immunofluorescence
Skin biopsies of 1 cm2 were excised 3dpd, embedded in cryostat medium Killik (Bio-Optica)
and rapidly frozen. 5μm sections were cut, processed as described [1] and incubated overnight
at 4˚C with anti-TCL1 (5A4 rat monoclonal antibody from Areta International), anti-phos-
pho-AKT (9271 Cell Signaling Technology), anti-cFOS (PC38 Calbiochem-MERK), anti-
cJUN (610326 BD biosciences), anti-phospho-cJUN (3270 Cell Signaling Technology), anti-
KRT6A (PRB-169P) or anti-KRT10 (PRB-159P Covance-Biolegend). FITC- or CY3- or
CY5-conjugated secondary antibodies were all from Jackson ImmunoResearch. The speci-
mens were observed by laser scanning confocal microscopy using a Zeiss LSM 510 Meta
microscope.
Colony-forming efficiency assay (CFE)
Freshly isolated KCs were low-density seeded in 6-well plates (500 cells/well in triplicate) and
cultured for two weeks. Cells were than fixed with 2% paraformaldehyde for 15 minutes and
stained with 1.5% Rhodamine B in water for 20 minutes. Colonies were counted and average
number of three independent experiments were graphed. In addition, the percentage of total
number of colonies developed from Tcl1-/-, with respect to WT or K14–TCL1 cells was calcu-
lated for each passage.
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Proliferation assay
Cryopreserved p0 KCs were plated in T25 cell culture flask. At p1 passage 0.5x104 cells were
seeded in 96-well plates, in triplicate. Subconfluent cells were starved for 16 hours in Cnt-57
basal medium (CELLnTEC, Switzerland), and then cultured with either 100 ng ml-1 of mouse
recombinant IGF-1 (Peprotech, UK) in basal medium, basal medium alone or complete
medium. After 24 hours, cells were fixed with 3% formaldehyde in PBS, then washed and
stained with 0.5% crystal violet solution for 30 minutes at RT. Samples were eluted with 100 μl
of 0.1M Na citrate in 50% ethanol pH 4.2 and Optical Density (OD) was measured at 595 nm
using a microplate reader BIO-RADModel 680. For each treatment, the differences in cell pro-
liferation between the three genotypes were evaluated as the ratio of OD values compared to
the WT. In addition, the effect of different treatments on the proliferation was evaluated, for
each genotype, as the OD ratio of the complete- or IGF1-treated vs basal value.
Statistical analysis
Statistical analysis was performed using GraphPad Prism 6 software. For CFE and proliferation
assays, statistical significance was determined by multiple T-test using the Holm-Sidak
method, with alpha = 5.000%. For Western blot analysis, significance was calculated by paired
T-test. Gene expression experiments were analyzed as described in the ‘microarray expression
profile’ paragraph of this section.
Results
The epidermis of Tcl1-/- mice shows defective proliferation and
differentiation signalling, as revealed by gene expression profiling (GEP)
In order to identify the molecular mechanisms involved in TCL1 function on skin homeostasis
of adult mice, we used pan-genomic Affymetrix Mouse Genome 430 2.0 arrays to generate
GEP of epidermal KCs obtained fromWT, Tcl1-/- and K14-TCL1mouse models [1].
The GEP of K14-TCL1KCs is more similar to the WT than to Tcl1-/-. Principal compo-
nents analysis (PCA) of the three groups, using Partek software, reveals clearly distinct cluster-
ing among them (Fig 1A), confirming a major role for Tcl1a in the epidermis. Moreover,
unsupervised hierarchical cluster analysis, using BRB software, shows that the GEP of mice
carrying the K14-TCL1 transgene is more similar to the WT than to the Tcl1-/- one (Fig 1B).
Supervised analysis generated a list of 271 genes differentially expressed betweenWT, Tcl1-/-
and K14-TCL1KCs (S3 Table, P<0.001). Two-sample comparison was also performed inWT
vs Tcl1-/-, WT vs K14-TCL1, and Tcl1-/- vs K14-TCL1mice (S4–S6 Tables, respectively). The
results of gene expression experiments were validated by real-time PCR for 10 genes, randomly
selected among the most up- or under-regulated ones (S1 Table).
To evaluate at what extent the restoration of TCL1A expression in the basal KCs is able to
rescue the Tcl1-/- GEP at the WT level, we performed an overall analysis of the genes listed in
S3 Table. We assigned each gene to the “rescued” or “not rescued” group (Fig 1C), based on
the following criteria: first, we restricted the analysis to the 93 genes with a FDR score lower
than 1.00e-05 and a fold change (FC) higher than 1.5 or lower than 0.75, regarding the Tcl1-/-
vs WT ratio; second, on the bases of pairwise significance, we considered “rescued” the genes
that were not significantly different betweenWT and K14-TCL1KCs, indicating they were
reverted at physiologic level, and “not rescued” the genes that were not significantly different
between Tcl1-/- and K14-TCL1 (16 and 15 genes, respectively). Additional 20 genes were con-
sidered “rescued” as their expression was reverted in the K14-TCL1 compared to the Tcl1-/-
although excessively, compared to the WT, most likely due to the over-expression of the
Tcl1 and murin skin homeostasis
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Fig 1. GEP analysis of the WT, Tcl1-/- and K14-TCL1keratinocytes. (A) PCA analysis obtained by Partek GS on the totality of the genes shows that K14-TCL1 (TG, blue
spheres), Tcl1-/- (KO, red spheres) andWT (green spheres) samples stay as three well-separated groups. (B) Unsupervised hierarchical analysis by R on the most
significant differentially expressed genes (31 genes, P<1e-07) shows that K14-TCL1KCs are more similar to WT than to Tcl1-/- ones. (C) Percentage of “rescued” and “not
rescued” genes in the K14-TCL1KCs among the 93 most significant and most differentially expressed genes between Tcl1-/- andWT KCs. See the text for further
explanation.
https://doi.org/10.1371/journal.pone.0204775.g001
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transgene. The remaining 42 genes were expressed in the K14-TCL1KCs at an intermediate
level between the WT and the Tcl1-/-. Among these, we arbitrarily considered the expression
of the K14-TCL1KCs’ genes to be “sufficiently” similar to the WT when the ratio to WT was
lower than the ratio to Tcl1-/-. In the last column of the S3 Table, the assignment for each gene
to the corresponding group is reported. These data indicate the Tcl1a loss to affect the expres-
sion of several genes in the mouse epidermis and the restoring of TCL1A expression in the
basal layer to rescue 55% of these genes (Fig 1C).
Gene ontology (GO) and pathway analyses define functional and molecular defects in
Tcl1-/- KCs. GO and pathway analyses were used to investigate the biological mechanisms
that might be influenced by Tcl1a loss- or gain-of-function. GO analysis was conducted with a
0.005 significance threshold for the gene sets. Among the GO terms, we focused on those with
a prevalence in the gene sets of either the over- or under-expressed genes ( 80%, gray marked
in the S7–S9 Tables). The analysis showed that Tcl1-/- mice are defective to WT in the kerati-
nocyte differentiation, epithelium development and cytoskeleton components, as well as in the
mitosis process. Conversely, genes involved in antigen processing, are over-expressed in
Tcl1-/- vs WT (S7 Table). Interestingly, when K14-TCL1mice are compared to WT, the defects
in differentiation, development and mitosis are no more found. The over-represented genes
are mainly involved in the response to stimuli, actin organization and locomotion. A slight
increase in the antigen presentation is still observed, even if the FCs of the annotated genes are
all but one lower than 1.15 (S8 Table). Comparison between mutant and transgenic mice strik-
ingly resembled that between Tcl1-/- andWT except for the downregulation of mitosis (S9
Table). Through pathway analysis, we identified gene sets that were significantly perturbed
(P<0.05). Complete lists of altered pathways in WT versus Tcl1-/-, WT versus K14-TCL1 and
Tcl1-/- versus K14-TCL1 are given in supplement (S10–S12 Tables, respectively). Focusing on
those involved in proliferation, differentiation and survival regulation, most of the altered
pathways belong to growth factor signaling (IGF1, EGF, PDGF, NGF), with MAPK/AP1 cas-
cade being also involved (Tables 1, 2 and 3, respectively).
These data strongly confirm, by a molecular point of view, the functional defects observed
in the Tcl1-/- and rescued in the K14-TCL1 mouse in vivo [1] and indicate the growth factor
and MAPK signaling among the major molecular deregulations due to Tcl1a loss.
Tcl1a loss affects the progenitor cell number and the proliferation rate of
murine keratinocytes
Previously, we found a lack of TA proliferating cells and a progressive loss of CD34+ SCs in
the hair follicles [1]. Taking advantage of the gene expression data described above, we exam-
ined the progenitor cell number in primary KCs isolated from Tcl1-/- and from K14-TCL1
mice compared to WT, through colony-forming efficiency (CFE) analysis (Fig 2A). Soon after
isolation (p0), Tcl1-/- KCs gave rise to 49%+/-18 and 58%+/-22 total number of colonies when
compared to WT and K14-TCL1 cells, respectively, although these differences were not signifi-
cant. The differences became striking at the first passage (p1) as Tcl1-/- colonies became
12%+/-5 and 15%+/-7 of the WT and K14-TCL1, respectively. Indeed, Tcl1-/- KCs showed no or
little variations in their CFE where WT and K14-TCL1 showed their peak. At p2, the difference
in CFE between TCL1-null and TCL1-expressing cells was decreased but still significant
(34%+/-6 and 25%+/-4 of WT and K14-TCL1, respectively). Thereafter, CFE values from the
three different types of cells tend to 0 in a similar way (CFE assay has been performed until
p10, not shown).
In addition, we analyzed KC growth rate in the three genotypes (Fig 2B). At p1 passage,
KCs were cultured in basal or complete medium for 24 hours. In basal medium, cells from
Tcl1 and murin skin homeostasis
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Table 1. Genes of S4 Table, with relations between Tcl1-/- andWT, are subdivided as pathways.
Biocarta Pathway Pathway description Number of
genes
LS permutation p-
value
KS permutation p-
value
Efron-Tibshirani’s GSA
test p-value
m_insulinPathway Insulin Signaling Pathway 10 0.00181 0.00356 < 0.005 (-)
m_tollpathway Toll-Like Receptor Pathway 10 0.00335 0.04491 < 0.005 (-)
m_igf1Pathway IGF-1 Signaling Pathway 11 0.00414 0.02449 < 0.005 (-)
m_keratinocytePathway Keratinocyte Differentiation 19 0.00582 0.08422 0.155 (-)
m_pdgfPathway PDGF Signaling Pathway 13 0.00704 0.05368 < 0.005 (-)
m_ngfPathway Nerve growth factor pathway (NGF) 10 0.00824 0.00356 < 0.005 (-)
m_egfPathway EGF Signaling Pathway 13 0.00901 0.15252 < 0.005 (-)
m_tnfr2Pathway TNFR2 Signaling Pathway 5 0.01526 0.12641 0.105 (-)
m_cdk5Pathway Phosphorylation of MEK1 by cdk5/p35 down
regulates the MAP kinase pathway
5 0.01881 0.07774 0.255 (+)
m_cd40Pathway CD40L Signaling Pathway 5 0.01954 0.12641 0.105 (-)
m_dspPathway Regulation of MAP Kinase Pathways Through Dual
Specificity Phosphatases
6 0.02606 0.4878 0.295 (+)
m_chemicalPathway Apoptotic Signaling in Response to DNA Damage 5 0.02607 0.20826 0.21 (-)
m_gleevecpathway Inhibition of Cellular Proliferation by Gleevec 11 0.03291 0.12153 < 0.005 (-)
m_gpcrPathway Signaling Pathway from G-Protein Families 8 0.03294 0.35841 0.115 (-)
m_mcmPathway CDK Regulation of DNA Replication 7 0.07259 0.16498 < 0.005 (+)
m_akap95Pathway AKAP95 role in mitosis and chromosome dynamics 5 0.10241 0.06738 < 0.005 (+)
m_rasPathway Ras Signaling Pathway 5 0.19114 0.06091 < 0.005 (+)
m_g1Pathway Cell Cycle: G1/S Check Point 13 0.23224 0.01245 0.125 (+)
m_RacCycDPathway Influence of Ras and Rho proteins on G1 to S
Transition
7 0.27633 0.02567 0.335 (+)
https://doi.org/10.1371/journal.pone.0204775.t001
Table 2. Genes of S5 Table, with relations between K14-TCL1 andWT, are subdivided as pathways.
Biocarta Pathway Pathway description Number of
genes
LS permutation p-
value
KS permutation p-
value
Efron-Tibshirani’s GSA
test p-value
m_akap95Pathway AKAP95 role in mitosis and chromosome dynamics 5 0.00419 0.02644 < 0.005 (+)
m_tollpathway Toll-Like Receptor Pathway 10 0.00553 0.07202 < 0.005 (-)
m_chemicalPathway Apoptotic Signaling in Response to DNA Damage 5 0.00695 0.03123 0.135 (-)
m_egfPathway EGF Signaling Pathway 13 0.00835 0.04904 < 0.005 (-)
m_cd40Pathway CD40L Signaling Pathway 5 0.01208 0.16315 0.065 (-)
m_tnfr2Pathway TNFR2 Signaling Pathway 5 0.01278 0.16315 0.23 (+)
m_pdgfPathway PDGF Signaling Pathway 13 0.01652 0.16707 < 0.005 (-)
m_dspPathway Regulation of MAP Kinase Pathways Through Dual
Specificity Phosphatases
6 0.01716 0.12992 0.18 (-)
m_gleevecpathway Inhibition of Cellular Proliferation by Gleevec 11 0.0199 0.16504 < 0.005 (-)
m_cdk5Pathway Phosphorylation of MEK1 by cdk5/p35 down
regulates the MAP kinase pathway
5 0.02752 0.15282 0.455 (-)
m_gpcrPathway Signaling Pathway from G-Protein Families 8 0.03275 0.21625 < 0.005 (-)
m_g2Pathway Cell Cycle: G2/M Checkpoint 9 0.03701 0.04128 0.065 (+)
m_ngfPathway Nerve growth factor pathway (NGF) 10 0.05594 0.25037 < 0.005 (-)
m_atmPathway ATM Signaling Pathway 10 0.15562 0.02225 0.105 (+)
m_igf1Pathway IGF-1 Signaling Pathway 11 0.23682 0.48638 < 0.005 (-)
m_fasPathway FAS signaling pathway (CD95) 8 0.25341 0.27857 < 0.005 (+)
m_tgfbPathway TGF beta signaling pathway 7 0.43 0.09677 < 0.005 (+)
https://doi.org/10.1371/journal.pone.0204775.t002
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Tcl1-/- mice grew less than the WT ones (0.53+/-0.02-fold change, P<0.005), while in K14-TCL1
cells the defect was less severe (0.73+/-0.18-fold change, not significant). When KCs were cul-
tured in complete medium, WT cells about doubled their proliferation rate, as well as
K14-TCL1 ones (1.92+/-0.13- and 2.18+/-0.14-fold change, respectively), while Tcl1-/- cells
showed a significant lower increase (1.31+/-0.17-fold change) (Fig 2B). Our GEP data showed
that the IGF1 pathway is one of the most altered in Tcl1-/- mice with respect to WT (Table 1).
Since, IGF1 is known to regulate epidermal proliferation [29, 30] we tested its ability to stimu-
late KCs with respect to basal medium condition. We found a similar proliferation increment
in WT and K14-TCL1 cells (1.62+/-0.06- and 1.4+/-0.07-fold change, respectively) while Tcl1-/-
cells were completely unresponsive (1.04+/-0.02-fold change).
Taken together, these results confirm an important role for TCL1 in maintaining KC pro-
genitor cells and its requirement as a proliferative factor, particularly when acting through the
IGF1 pathway.
The expression of differentiation markers is altered in Tcl1a mouse models
Our GO analysis showed that modulation of Tcl1a expression has consequences in KCs differ-
entiation. Hence, we examined the pattern of expression of differentiation markers that iden-
tify upper epidermal layers (spinous and granular) (Fig 3A–3C). Cytokeratin 6 (KRT6) is
considered as an activation marker for KCs [31, 32] and is one of the most differentially
expressed gene in our GEP analysis (S3–S6 Tables). Accordingly, KRT6 immunofluorescence
in 3-day post-depilation (3dpd) skin samples shows localized expression in epidermis sur-
rounding hair follicles in WTmice, while only few scattered cells express KRT6 in Tcl1-/-
mice. Interestingly, K14-TCL1mice show strong and diffuse KRT6 immunoreactivity, in all
the epidermis (Fig 3A). WB analysis of epidermal sheet samples 3dpd, confirmed the expres-
sion of KRT6 to be dramatically reduced in Tcl1-/- mice and highly overexpressed in
K14-TCL1with respect to WTmice (0.36- and 8-fold change, respectively, Fig 3C). Cytokera-
tin 10 (KRT10) is one of the first differentiation marker to be expressed by post-mitotic cells in
spinous layer and it has a role in proliferation control [33]. Immunofluorescence confirmed
supra-basal expression of KRT10 in all three genotypes (Fig 3B). In this case, WB analysis
showed both Tcl1-/- and K14-TCL1mice to have more than 2-fold change in KRT10 expres-
sion with respect toWTmice (2.8- and 2.2-fold, respectively) (Fig 3C). FLG and IVL are termi-
nal differentiation markers of granular layer, but are regulated in an opposite way in Tcl1a
mouse models. WB experiments showed that FLG is more expressed in K14-TCL1mice
Table 3. Genes of S6 Table, with relations between Tcl1-/- and K14-TCL1 are subdivided as pathways.
Biocarta Pathway Pathway description Number of
genes
LS permutation p-
value
KS permutation p-
value
Efron-Tibshirani’s GSA test p-
value
m_pdgfPathway PDGF Signaling Pathway 13 0.01738 0.06222 0.24 (-)
m_egfPathway EGF Signaling Pathway 13 0.01881 0.06222 0.235 (-)
m_insulinPathway Insulin Signaling Pathway 10 0.04619 0.07895 0.14 (-)
m_igf1Pathway IGF-1 Signaling Pathway 11 0.05016 0.04466 0.21 (-)
m_wntPathway WNT Signaling Pathway 8 0.06155 0.0295 0.05 (+)
m_g2Pathway Cell Cycle: G2/M Checkpoint 9 0.08182 0.01766 0.49 (+)
m_akap95Pathway AKAP95 role in mitosis and chromosome
dynamics
5 0.0887 0.00149 0.47 (+)
m_cd40Pathway CD40L Signaling Pathway 5 0.11107 0.02473 0.14 (-)
m_aktPathway AKT Signaling Pathway 6 0.19848 0.00206 0.06 (+)
m_erkPathway Erk1/Erk2 Mapk Signaling pathway 6 0.29669 0.04846 0.39 (+)
https://doi.org/10.1371/journal.pone.0204775.t003
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(3-fold) and less in Tcl1-/- mice (0.4-fold), when compared to WT; conversely, IVL is aug-
mented in Tcl1-/- KCs (4-fold), while it is almost undetectable in K14-TCL1 ones (0.12-fold)
(Fig 3C). Overall, these data demonstrate that TCL1 is profoundly involved in the regulation
of both early and terminal KC differentiation programs.
Finally, we previously observed that basal KCs in the epidermis of Tcl1-/- mice aberrantly
co-express proliferation and apoptosis markers in vivo [1]. Moreover, there are evidences for
TCL1 anti-apoptotic effect through the decrease of PARP1 cleavage in humans [25]. Consis-
tently with this function, by WB experiments in 3dpd epidermis, we found that the percentage
of PARP1 cleavage in Tcl1-/- is higher than in WT (63% and 35%, respectively), while in
K14-TCL1 it is comparable toWT (38%) (Fig 3D). Similar results were obtained analyzing Cas-
pase 3 cleavage (69%, 33% and 37%, respectively). Hence, these experiments confirm the anti-
apoptotic role of TCL1 in murine KCs.
TCL1 modulation affects the phosphorylation levels of ERK1/2, SAPK/JNK
and P38 MAPK
Unlike the TCL1 function in the immune system [22], when we analyzed AKT activation in
mutant and transgenic KCs by kinase assay, we didn’t find significant differences with respect
to WT (Panel A in S1 Fig). Consistently with this result, phosphorylated AKT(Ser473) does
not co-localize with TCL1 in WT follicular keratinocytes, analyzed by immunofluorescence
(Panel B in S1 Fig). Moreover, pathway analysis have not pointed out the AKT signaling
among those affected by TCL1 modulation. Rather, our GEP data have highlighted the
involvement of MAPKs in response to Tcl1a modulation. The MAPK cascade has a central
role on the regulation of differentiation and programmed cell death in the epidermis, through
the phosphorylation of ERK1/2, SAPK/JNK and P38 [34].
Thus, we investigated byWB analysis the phosphorylation rate of ERK1/2, SAPK/JNK and
P38 MAPKs in KCs from Tcl1-/- and K14-TCL1mice, compared to the WT samples (Fig 4).
We found that Tcl1a loss increased the P38 phosphorylation rate when compared to WT and
K14-TCL1mice by 7.2- and 2.8-fold, respectively (Fig 4A and 4C). On the opposite, the over-
expression of TCL1A induced a 32-fold increased ERK1/2 (Fig 4A–4C) and a 2.6-fold
increased SAPK/JNK (Fig 4B and 4C) phosphorylation with respect to WT. Normalized opti-
cal density values (OD) of the phosphorylated and entire forms are given in supplement (Pan-
els A, B and C in S2 Fig). The graph in Fig 4C shows the phosphorylation rate for these
proteins calculated as the OD ratio of phosphorylated to entire form. These results indicate
that in the absence of Tcl1a, P38 route is hyper-activated, leaving unaffected ERK1/2 and
SAPK/JNK signaling. On the other hand, over-expression of TCL1A in the basal KCs partially
restores the phosphorylation of P38 to WT levels and enhances the activation of ERK1/2 and
SAPK/JNK.
TCL1 inhibits cFOS expression and its nuclear localization and induces
cJUN phosphorylation
The activator protein 1 (AP1) transcriptional complex represents one of the main effector of
the MAPK signaling cascade in the epidermis [34, 35]. Since our GEP data show 8.4-fold
Fig 2. Colony-forming efficiency (CFE) and proliferation are impaired in Tcl1-/- mice. (A) CFE assay performed on first three passages KCs of WT (circles), Tcl1-/-
(squares) and K14-TCL1; Tcl1-/- (triangles down) mice; values are expressed as total number of colonies; CFE of WT and K14-TCL1 are significantly different with
respect to Tcl1-/- at passages p1 and p2 (⇤P<0.001; ⇤⇤P<0.005). (B) Proliferation in cultured KCs fromWT (dark gray), Tcl1-/- (black) or K14-TCL1 (light gray) mice.
KCs at p1 passage were cultured in basal medium, in complete medium, or in basal medium plus 100 ng ml-1 IGF-1; OD values are reported. All experiments were
performed in triplicates. Significant growth differences between the groups are indicated (⇤P<0.001; ⇤⇤P<0.005).
https://doi.org/10.1371/journal.pone.0204775.g002
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Fig 3. Differentiation and apoptosis are altered in Tcl1-/- KCs. Immunofluorescence for the activation marker KRT6 (green) (A) or the differentiation marker KRT10
(green) (B) on epidermis of WT, Tcl1-/- and K14-TCL1mice. Nuclear counterstain is propidium iodide (red). Magnification: 40X. Images were acquired by confocal laser
scanning. Representative images of three experiments are shown. (C) Western blot analysis on protein extracts of epidermal sheet fromWT, K14-TCL1 (K14) and Tcl1-/-
(-/-) mice for differentiation markers. The results were calculated as fold change of the K14-TCL1or Tcl1-/- to theWT OD values. Samples were analyzed also for PARP1
and CASP3 apoptosis markers (D). C-PARP1 and C-CASP3 are the cleaved forms. The results were calculated as percentage of the cleaved form to the sum of cleaved and
entire normalized OD values.
https://doi.org/10.1371/journal.pone.0204775.g003
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increased cFosmRNA in Tcl1-/- mice with respect to WT (S4 Table), we investigated changes
in the main AP1 subunits cFOS and cJUN.
We analyzed the cFOS protein by confocal analysis on 3dpd skin samples from the three
genotypes (Fig 5A). The first evidence is that, accordingly to mRNA data, cFOS expression is
enhanced in Tcl1-/- when compared to WT, also at the protein level and it is only partially
restored in K14-TCL1mice. Interestingly, we also found that, in the WT skin, cFOS cellular
localization is totally restricted to the cytoplasmic compartment of the basal layer. In the WT
panel of Fig 5A the green fluorescence, representing cFOS staining, is all around the blue fluo-
rescence of the nuclei. Conversely, in the absence of Tcl1a, cFOS is strongly localized to the
nuclear compartment of the cell visualized as light blue fluorescence in Fig 5A. In the
K14-TCL1 panel, the cFOS staining pattern is intermediate between WT and Tcl1-/- samples.
These data suggest the TCL1-mediated inhibition of cFOS transcriptional activity occurring in
human B-CLL [25], might be functional in the murine KCs as well. When we analyzed cJUN
expression in the skin of the three mouse models, we observed comparable levels of cJUN total
protein, which was restricted to the cytoplasm of basal KCs in all samples (Fig 5B). On the con-
trary, cJUN phosphorylation was associated with nuclear localization and the number of posi-
tive cells was found decreased in Tcl1-/- and increased in K14-TCL1KCs, when compared to
the WT counterpart. To confirm and quantify this difference, we analyzed cJUN phosphoryla-
tion rate by WB and we found a 0.7-fold decreased cJUN phosphorylation in Tcl1-/- KCs,
when compared to the WT (Fig 5C and 5D). At the same time, over-expression of TCL1A
leads to a 1.9- and 1.3-fold increased cJUN phosphorylation rate when compared to Tcl1-/-
andWT, respectively. Normalized OD values of the phosphorylated and entire forms are given
in supplement (Panel D in S2 Fig). These experiments show that TCL1 takes part in AP1 regu-
lation, by controlling both cFOS localization and cJUN phosphorylation.
Discussion
Previously we showed that adult Tcl1-/- mice developed skin defects due to dramatic reduction
of CD34 stem cell marker and proliferating TA cells in the hair follicle, as well as dysregulated
proliferation/differentiation/apoptosis program in the interfollicular epidermis [1]. In this
work, we finally demonstrated that Tcl1a is required for the correct programming and com-
mitment of the epidermal KCs.
The GEP analysis shows that Tcl1a loss provokes profound gene expression deregulation in
the epidermal tissue. Furthermore, the mouse model carrying the K14-driven TCL1A gene in a
Tcl1a null background is more similar to the WT than to the Tcl1-/- one, therefore giving a
first general statistical confirmation of the previously observed ability of the K14-TCL1 trans-
genic mouse to rescue the Tcl1-/- mutant phenotype. In particular, the expression of 55% of
genes deregulated in the Tcl1-/- are restored in K14-TCL1KCs. Among these, 36 genes (39%)
are completely rescued at physiologic level or overturned, suggesting a close relationship with
TCL1. Interestingly, 29 out of these 36 genes were downregulated in the Tcl1-/- KCs, confirm-
ing the role for TCL1 as a transcription activator [25] also in epidermal cells. On the other
hand, the K14-TCL1mouse is not able to rescue all the genes affected by the absence of Tcl1a,
especially those over-expressed, suggesting that the presence of Tcl1a is necessary, but not
Fig 4. MAPKs phosphorylation pattern is modified by TCL1 loss- or gain-of function.Western blot analysis of
phosphorylated forms of P38, ERK1/2 (A) and SAPK/JNKMAPKs (B) on protein extracts from keratinocytes of WT,
Tcl1-/- and K14-TCL1mice. Tubulin alpha (ċTUB) was used to normalize protein load. (C) Normalized OD values
were used to calculate the ratio of phosphorylated to entire forms and graphed as the mean and standard deviation of
three independent experiments for the WT (dark gray), Tcl1-/- (light gray) and K14-TCL1 (black) KCs.
https://doi.org/10.1371/journal.pone.0204775.g004
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sufficient, for these factors. Another possibility is that the K14-driven TCL1A is unable to regu-
late factors acting in supra-basal layers due to its expression limited to basal layer.
At the functional level, the GO analysis pointed out the differentiation and cell division as
two functions defective in Tcl1-/- KCs, which are rescued in the K14-TCL1. In contrast with
the T and B cell TCL1A transgenic models, overexpression in epidermal KCs did not induce
hyper-proliferation, nor did we observe skin tumours formation in the K14-TCL1mice [1].
This phenotype is in agreement with our GEP data and GO analysis and might be due to a
milder activity of the K14 promoter with respect to the lck or Eμ ones. Alternatively, the prolif-
eration/survival programs in the KCs might be subjected to a tight control, able to overcome
the TCL1A overexpression. Rather, the over-represented genes belong to the response to stim-
ulus and cell motility GO terms, with no evidence for any aberrant phenotype.
Krt6 is one of the most significant differentially expressed gene found by our GEP analysis.
Krt6 is not constitutively expressed in the skin, but is rapidly induced after injury of the epider-
mis (e.g. waxing) and is considered a marker of KCs activation both for proliferation and for
differentiation [31, 32]. Interestingly, we observed that in 3dpdWT epidermis, KRT6 protein
is mainly expressed by basal cells and maintained in some supra-basal cells; in Tcl1-/- epider-
mis, KRT6 expression is dramatically reduced and in K14-TCL1, KRT6 is highly expressed in
all the layers. Thus, KRT6 expression is strongly dependent from TCL1 regulation, is induced
in the basal layer and maintained in supra-basal layers, indicating that KRT6 might be a good
candidate, at least in part, for the observed differentiative and/or proliferative phenotypes.
Conversely, the supra-basal marker KRT10 is increased in Tcl1-/- as well as in K14-TCL1
mouse, when compared to WT, suggesting to exemplify the above mentioned ‘not rescued’
over-expressed genes. Yet, the expression of the terminal differentiation markers FLG and IVL
are altered in Tcl1-/- but rescued in K14-TCL1mouse, suggesting that in supra-basal KCs,
some differentiation programs might be activated from the basal layer. Apoptosis signaling
represents another interesting example of the basal/supra-basal stratification affected by Tcl1a
loss. In our previous work, we observed proliferative marker coexisting with apoptotic events
in basal layer of Tcl1-/- mouse, although programmed cell death is normally activated in termi-
nally differentiated layer only. This aberration was rescued by K14-driven TCL1A over-expres-
sion [1]. Here, we showed that the apoptotic factors PARP1 and CASP3 are abnormally
activated in Tcl1-/- KCs with respect to WT and the K14-TCL1 expression is sufficient to
restore physiologic activation levels, resembling the TCL1 anti-apoptotic effect observed in
human CLL [25].
Proliferation is another defective function we described in the Tcl1-/- skin [1], which has
been pointed out also in this work by the GO analysis. Accordingly, primary KCs from Tcl1-/-
mice are almost unable to form colonies or to proliferate when placed in complete media. On
the other hand, this phenotype is completely rescued when TCL1A is reinserted in basal cells
of K14-TCL1mouse, mimicking the WT behavior. These experiments confirmed the TCL1A
overexpression to induce no hyper-proliferation in KCs. Pathway analysis identified growth
factor and MAPK as some of the most significantly pathways altered in the Tcl1-/- KCs. Since
IGF1 is known to regulate epidermal proliferation, motility, and progenitor cell behaviour, act-
ing through MAPK-AP1 and/or PI3K-AKT pathways [29, 30, 36, 37], we focused on
Fig 5. cFos and cJUN AP1 components are affected by TCL1 loss- or gain-of function through different mechanisms. (A) Immunofluorescence of
cFOS (green), or (B) cJUN (red) and phospho-cJUN (green) onWT, Tcl1-/- and K14-TCL1mice epidermis. Nuclear counterstain is propidium iodide
(blue).Merging of green and blue fluorescence represents nuclear localization (light blue). Magnification: 40X. Images were acquired by confocal laser
scanning. (C) Western blot analysis of cJUN and phospho-cJUN on protein extracts of KCs fromWT, Tcl1-/- and K14-TCL1mice. (D) Normalized OD
values were used to calculate the ratio of phosphorylated to entire form and graphed as the mean and standard deviation of three independent experiments
for theWT (dark gray), Tcl1-/- (light gray) and K14-TCL1 (black) mice.
https://doi.org/10.1371/journal.pone.0204775.g005
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IGF1-induced proliferation. Interestingly, we found a proliferation pattern closely resembling
that obtained with serum stimulation, with impaired proliferation of Tcl1-/- KCs, which was
significantly rescued by K14-TCL1 expression. This finding demonstrates that Tcl1a gene is
definitely necessary for KCs proliferation both by serum- or IGF1-induction.
Actually, despite the most known TCL1 function is to enhance AKT kinase activity [21, 23],
we did not found any difference in the AKT kinase activity between the three mouse models.
This finding is consistent with the two-cell embryo model, which showed no differences
between the phosphorylated AKT content of Tcl1-/- andWTmice [20]. Noguchi et al. had pro-
posed that the AKT kinase activity maintained in the Tcl1a null mice might be due in part to
the presence of five TCL1B family proteins and MTCP1 in the mouse genome [38]. Accord-
ingly, we had reported the high level expression of the Tcl1B2 isoform in the mouse epidermis,
especially in the Tcl1-/- one [1].
As for IGF1, most of the incoming signals that regulate proliferation, differentiation, and
apoptosis in the interfollicular epidermis are shuttled through the three major MAPK cascades
ERK1/2, SAPK/JNK, and P38 with several interconnections among the cascades [39]. ERK1/2
activation primarily mediates proliferative and survival signals from a range of different sur-
face molecules, including growth factors and cellular adhesion proteins; on the other hand,
P38 MAPK-dependent mechanisms are mainly involved in regulating differentiation and apo-
ptosis processes [34, 40–43]. SAPK/JNK is able to regulate proliferation, differentiation, sur-
vival and/or migration, thus tuning a variety of processes such as tissue homeostasis, cell
metabolism, inflammation and carcinogenesis [44]. The relative activities of MAPKs can be
evaluated by their phosphorylation rate and here we provide evidences that Tcl1-/- mouse
shows a hyper-activation of P38 MAPK, which might be responsible for the apoptotic pheno-
type observed. Additionally, P38 hyper-phosphorylation might account for differentiative dis-
orders such as IVL overexpression [45]. On the converse, the overexpression of TCL1A by
K14-driven transgene increases ERK1/2 and SAPK/JNK phosphorylation. That TCL1 may
influence ERK1/2 phosphorylation was observed also in B-CLL, where the TCL1-targeting
microRNA-181b decreased phospho-ERK1/2 as well [46]. Thus, TCL1 could act as a prolifer-
ative/pro-survival factor and a differentiation regulator by increasing the phosphorylation on
ERK1/2 and SAPK/JNK and maintaining low levels of phospho-P38.
In epidermal KCs, downstream targets of MAPK signalling are primarily represented by
AP1 transcription factor, which is composed of homo- or hetero-dimers mainly belonging to
the FOS and JUN protein families. MAPKs can both affect AP1 activity, by direct phosphoryla-
tion, and by transcriptional activation of the promoters of specific AP1 components. Multiple
AP1 family members are expressed in the epidermis and form different dimer pairs, regulating
expression of several target genes and controlling KC functions [45, 47, 48]. It is not by hap-
hazard that by chip analysis we have found, among the most dysregulated genes, several factors
participating to the MAPK signaling and, in particular, the AP1 effector cFos. Nevertheless,
TCL1 has been reported to bind cFOS directly, thus inhibiting apoptosis [25, 49]. Our data are
consistent with this observation and we can hypothesize that TCL1 prevents cFOS transcrip-
tional function by sequestering this factor into the cytoplasm, having cFOS mainly nuclear
localization in the Tcl1-/- epidermal KCs. This phenotype is rescued, although not entirely, in
the K14-TCL1mice. Moreover, we have shown that phosphorylation of cJUN is reduced in the
absence of Tcl1a and increased once TCL1A has been reintroduced into the KCs. Hence, in
mouse KCs TCL1 seems to have a stimulating rather than an inhibitory effect on cJUN activity
that was seen in B-CLL by Pekarsky et al. [25]. This would be consistent with a role for cJUN
in proliferation, differentiation and wound healing, in mouse epidermal cells [50–52].
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Conclusions
In conclusion, analyzing the effects of altered Tcl1a gene expression in knockout or transgenic
mouse models, we have demonstrated, for the first time, that TCL1 is a major factor on epider-
mal KCs’ proliferation, in particular when serum- or IGF1-stimulated. Additionally, Tcl1a loss
is associated with differentiation disorders and uncontrolled apoptosis. Conversely, overex-
pression of TCL1A is able to rescue almost completely the mutant defects and do not show any
evident aberration. Our data suggest that TCL1 function in KCs is exerted, at least in part, by
regulating the MAPK phosphorylation balance between ERK1/2, SAPK/JNK and p38, the
phosphorylation rate of cJUN and the cellular localization of cFOS, that means multilevel con-
trol of the activity of the MAPK/AP1 axis. Whether the role of TCL1 is due to direct interac-
tions with the MAPK factors above mentioned or with the AP1 subunits, cJUN and cFOS, will
be the object of further investigations. Finally, we intend to analyze TCL1 role also in the
human hair follicle and epidermis from skin tissues of both healthy donors and patients
affected by skin diseases.
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